Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
In idiopathic Parkinson's disease massive cell death occurs in the dopamine-containing substantia nigra. A link between the vulnerability of nigral neurons and the prominent pigmentation of the substantia nigra, though long suspected, has not been proved. This possibility is supported by evidence that N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its metabolite MPP+, the latter of which causes destruction of nigral neurons, bind to neuromelanin. We have directly tested this hypothesis by a quantitative analysis of neuromelanin-pigmented neurons in control and parkinsonian midbrains. The findings demonstrate first that the dopamine-containing cell groups of the normal human midbrain differ markedly from each other in the percentage of neuromelanin-pigmented neurons they contain. Second, the estimated cell loss in these cell groups in Parkinson's disease is directly correlated (r = 0.97, P = 0.0057) with the percentage of neuromelanin-pigmented neurons normally present in them. Third, within each cell group in the Parkinson's brains, there is greater relative sparing of non-pigmented than of neuromelanin-pigmented neurons. This evidence suggests a selective vulnerability of the neuromelanin-pigmented subpopulation of dopamine-containing mesencephalic neurons in Parkinson's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The nigra’s neuromelanin derives from dopamine and occurs in autolysosomes rather than melanosomes (226).”
From Chemiexcitation: Mammalian Photochemistry in the Dark† (2023) · cites this paper as [226]
In the citing paper
“The concept of such a substantial loss of EC neurons before AD symptoms occur may be analogous to the observation that very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
In the citing paper
“very substantial neuronal losses are present in the substantia nigra before extrapyramidal symptoms become apparent in Parkinson's disease (Hirsch et al., 1988).”
From Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease (1996) · cites this paper as Hirsch et al., 1988
Citations
Cites
Dahlstroem, A., & Fuxé, K. (1964) · PubMed · Cited by 5,133
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Recent developments in Parkinson's disease
Fahn, S., Elton, R., MARSDEN, C. D., Calne, D. B., & Goldstein, M. (1986) · Raven Press eBooks · Cited by 2,306
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
STEELE, J. C. (1964) · Archives of Neurology · doi:10.1001/archneur.1964.00460160003001 · Cited by 1,924
Recent Developments in Parkinson's Disease
Hurtig, H. I. (1987) · Neurology · doi:10.1212/wnl.37.5.893 · Cited by 1,920
Emson, P., Heffher, R. R., & Pearson, J. (1984) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198409000-00010 · Cited by 1,648
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Gerfen, C., Herkenham, M., & Thibault, J. (1987) · The Journal of Neuroscience · doi:10.1523/jneurosci.07-12-03915.1987 · Cited by 803
Hirsch, E. C., Graybiel, A. M., Duyckaerts, C., & Javoy-Agid, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.16.5976 · Cited by 554
Self-citation
Research works printed but not linked: 6
- Escourolle, R., De Recondo, J. & Gray, F. in Monoamines Noyaux gris cenlraux et syndromes de Parkinson (eds de Ajuriaguerra, J. & Gauthier, G.) 173–229 (Geneva, 1970).
- Marsden, C. D. J. Neural Trans. Suppl. 19, 121–141 (1983).
- Dahlström, A. & Fuxe, K. Acta physiol. scand. 62, (Suppl. 232) 1–55 (1964).
- Graybiel, A. M. & Ragsdale, C. W. Jr in Chemical Neuroanalomy (ed. Emson, P. C.) 427–504 (Raven, New York, 1983).
- Graham, D. G. Molec. Pharmacol. 14, 633–643 (1978).
- Lindquist, N. G. Acta radiol. Suppl. 325, 1–92 (1973).
Cited by
Items 701–800 of 1,000
Kourosh‐Arami, M., Komaki, A., & Zarrindast, M. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220418115503 · Cited by 40
Cui, H., Cui, Y., Sun, Y., et al. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/21/215601 · Cited by 30
Altered regulation of iron transport and storage in Parkinson’s disease
Hirsch, É. C. (2006) · Springer eBooks · doi:10.1007/978-3-211-33328-0_21 · Cited by 35
“Yet evidence suggests that the loss of these neurons is heterogeneous across different catecholaminergic cell groups (Hirsch et al., 1988).”
BackgroundNADH fluorescence lifetime is an endogenous reporter of α‐synuclein aggregation in live cells
Plotegher, N., Stringari, C., Jahid, S., Veronesi, M., Girotto, S., Gratton, E., & Bubacco, L. (2015) · The FASEB Journal · doi:10.1096/fj.14-260281 · Cited by 31
“Moreover, PD is characterized by 1) the prevalent death of dopaminergic neurons in the substantia nigra pars compacta and by 2) the presence of intraneuronal inclusions containing protein aggregates, termed Lewy bodies (LBs), in parkinsonian brains (8).”
BackgroundNeuropathology of Movement Disorders
Jellinger, K. A. (1998) · Neurosurgery Clinics of North America · doi:10.1016/s1042-3680(18)30262-6 · Cited by 30
Picada, J. N., Schröder, N., Izquierdo, I., Henriques, J. A. P., & Roesler, R. (2002) · European Journal of Pharmacology · doi:10.1016/s0014-2999(02)01553-4 · Cited by 30
Parkinsonian patients report blunted subjective effects of methylphenidate.
Persico, A. M., Reich, S., Henningfield, J. E., Kuhar, M. J., & Uhl, G. R. (1998) · Experimental and Clinical Psychopharmacology · doi:10.1037//1064-1297.6.1.54 · Cited by 30
Myelin-associated glycoprotein inhibits neurite/axon growth and causes growth cone collapse
Li, M., Shibata, A., Li, C., Braun, P. E., McKerracher, L., Roder, J., Kater, S. B., & David, S. (1996) · Journal of Neuroscience Research · doi:10.1002/(sici)1097-4547(19961115)46:4<404::aid-jnr2>3.0.co;2-k · Cited by 191
Laguna, A., Peñuelas, N., González-Sepúlveda, M., Nicolau, A., Arthaud, S., Guillard-Sirieix, C., Picón, M. L., Compte, J., Miquel-Rio, L., Xicoy, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53168-7 · Cited by 35
“…disease and brain aging, including their long and diffuse axonal projections, intrinsicpacemakeractivityandhighmetabolicdemand 3 ,thepresence of conspicuous intracellular pigment deposits has long been suspected as a key vulnerability factor contributing to their early and extensive demise 13 .”
Sroysee, W., Chairam, S., Amatatongchai, M., Jarujamrus, P., Tamuang, S., Pimmongkol, S., Chuaitammakit, L. C., & Somsook, E. (2016) · Journal of Saudi Chemical Society · doi:10.1016/j.jscs.2016.02.003 · Cited by 30
“The neurotransmitter DA is a precursor for catecholamine synthesis, for example, of epinephrine and norepinephrine; disorders in DA synthesis can lead to Parkinson’s disease [1].”
A monolayer hiPSC culture system for autophagy/mitophagy studies in human dopaminergic neurons
Stathakos, P., Jiménez-Moreno, N., Crompton, L. A., Nistor, P., Badger, J. L., Barbuti, P. A., Kerrigan, T. L., Randall, A. D., Caldwell, M. A., & Lane, J. D. (2020) · Autophagy · doi:10.1080/15548627.2020.1739441 · Cited by 32
“In PD, the most susceptible neurons are the neuromelaninpigmented mDANs located in the substantia nigra pars compacta (SNpc; A9) [3].”
BackgroundRahman, M., Chakraborti, R. R., Potol, M. A., Abir, A. H., Sharmin, O., Alam, M., Khan, M. F. R., Afrin, R., Jannat, H., Wadud, R., et al. (2019) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12097 · Cited by 31
Modern Brainstem MRI Techniques for the Diagnosis of Parkinson's Disease and Parkinsonisms
Arribarat, G., Barros, A. D., & Péran, P. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00791 · Cited by 30
Psychosis‐Like Behavior and Hyperdopaminergic Dysregulation in Human α‐Synuclein BAC Transgenic Rats
Polissidis, A., Koronaiou, M., Kollia, V., Koronaiou, E., Nakos‐Bimpos, M., Bogiongko, M., Vrettou, S., Karali, K., Casadei, N., Rieß, O., et al. (2020) · Movement Disorders · doi:10.1002/mds.28383 · Cited by 33
“Similar to our in vivo findings, in PD, there is a selective vulnerability of midbrain nigral neurons and relative sparing of VTA neurons.(55) Whether this premotor hyperdopaminergic state preferentially affects the nigrostriatal or the mesostriatal or even the mesocortical pathway or olfactory bulb DAergic circuitry,…”
ResultMeurers, B. H., Dziewczapolski, G., Shi, T., Bittner, A., Kamme, F., & Shults, C. W. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5310-08.2009 · Cited by 31
“Dopamine (DA), a slow-acting neurotransmitter, provides critical input into the system as is evident from the loss of dopaminergic midbrain neurons in Parkinson’s disease (PD) (Hirsch et al., 1988).”
BackgroundCebrián, C., & Prensa, L. (2009) · The Journal of Comparative Neurology · doi:10.1002/cne.22275 · Cited by 30
“This particular subset of clustered SNc neurons is the most prone to degeneration in sporadic PD (Hirsch et al., 1988; Gibb et al., 1990; Fearnley and Lees, 1991; Gibb and Lee, 1991; Rinne, 1993; Damier et al., 1999a,b), and nigrostriatal axons arising from neurons located within these clusters…”
BackgroundSound lateralization in Parkinson's disease
Lewald, J., Schirm, S. N., & Schwarz, M. (2004) · Cognitive Brain Research · doi:10.1016/j.cogbrainres.2004.06.008 · Cited by 31
Orexinergic Input to Dopaminergic Neurons of the Human Ventral Tegmental Area
Hrabovszky, E., Molnár, C. S., Borsay, B. Á., Gergely, P. A., Herczeg, L., & Liposits, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083029 · Cited by 32
“DA cells in the human SN tend to accumulate more neuromelanin pigment, in comparison with DA neurons of the VTA [47] which latter contain higher levels of vesicular monoamine transporter-2 for the vesicular packaging of dopamine and DOPA [48].”
Yasmin, A., Barman, S., Barman, B. K., & Roy, M. N. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.08.114 · Cited by 29
Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity
Tribl, F., Marcus, K., Bringmann, G., Meyer, H. E., Gerlach, M., & Riederer, P. F. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0513-7 · Cited by 32
“, 1995), but only a few of the SN cells represent the dopaminergic neurons, which selectively degenerate in PD (Bj€orklund and Lindvall, 1984; Braak and Braak, 1986; Hirsch et al., 1988; Kastner et al., 1992) (Fig.”
BackgroundYamada, M., Yamada, M., & Richelson, E. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00395-l · Cited by 30
Nappi, A. J., & Vass, E. (1994) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(94)90082-5 · Cited by 29
Tong, Z.-Y., Kingsbury, A. E., & Foster, O. J. F. (2000) · Molecular Brain Research · doi:10.1016/s0169-328x(00)00089-9 · Cited by 28
Neuroprotection for Parkinson’s disease: a new approach for a new millennium
Drukarch, B., & Muiswinkel, F. L. V. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.10.1855 · Cited by 31
Conserved and cell type-specific transcriptional responses to IFN-γ in the ventral midbrain
Hobson, B. D., Stanley, A. T., Santos, M. B. D. L., Culbertson, B., Mosharov, E. V., Sims, P. A., & Sulzer, D. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.04.008 · Cited by 31
Depboylu, C., Rösler, T. W., de Andrade, A., Oertel, W. H., & Höglinger, G. U. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13026 · Cited by 28
Lü, L., Neff, F., Alvarez‐Fischer, D., Henze, C., Hirsch, É. C., Oertel, W. H., Schlegel, J., & Hartmann, A. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.04.002 · Cited by 29
“%) in PD (Hirsch et al., 1988).”
Chae, S., Kang, B. Y., Hwang, O., & Choi, H. J. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.03.031 · Cited by 31
VTA neurons show a potentially protective transcriptional response to MPTP
Phani, S., Gonye, G. E., & Iacovitti, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.04.061 · Cited by 27
“…in humans, nonhuman primates, and certain rodents by the neurotoxin 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Elsworth et al., 1987; Hirsch et al., 1988; Jacobowitz et al., 1984; Schneider et al., 1987), raising the interesting hypothesis that there are factors intrinsic to the VTA…”
BackgroundRole of Nurr1 in the Generation and Differentiation of Dopaminergic Neurons from Stem Cells
Rodríguez‐Traver, E., Solís, Ó., Díaz‐Guerra, E., Ortiz, Ó., Vergaño‐Vera, E., Méndez‐Gómez, H. R., García‐Sanz, P., Moratalla, R., & Vicario‐Abejón, C. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9586-0 · Cited by 31
Schechter, M., Grigoletto, J., Elhadi, S. A., Glickstein, H., Friedman, A., Serrano, G. E., Beach, T. G., & Sharon, R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00370-y · Cited by 32
Kim, S. W., Jang, Y. J., Chang, J. W., & Hwang, O. (2003) · Neurobiology of Disease · doi:10.1016/s0969-9961(03)00037-8 · Cited by 31
“In vivo, the nigral dopaminergic neurons are under a substantial level of oxidative stress owing to oxidation of dopamine (Hirsch et al. 1988), producing the highly reactive quinones and hydrogen peroxide during its auto- and enzymatic oxidations (Stokes et al.”
Goto, S., & Hirano, A. (1991) · Annals of Neurology · doi:10.1002/ana.410300211 · Cited by 28
Aluminum Enhances Melanin-Induced Lipid Peroxidation
Meglio, L., & Oteiza, P. I. (1999) · Neurochemical Research · doi:10.1023/a:1021000709082 · Cited by 30
“The report that the relative neuronal survival in substantia nigra is significantly lower in neuromelanin-pigmented neurons than in non pigmented cells (34) suggests that neuromelanin has a role in mediating neuronal death.”
BackgroundNaoi, M., Maruyama, W., & Dostert, P. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90591-6 · Cited by 30
Sian‐Hülsmann, J., & Riederer, P. F. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-023-02723-5 · Cited by 32
Pain in Parkinson's disease: a neuroanatomy-based approach
Nardelli, D., Gambioli, F., Bartolo, M. I. D., Mancinelli, R., Biagioni, F., Carotti, S., Falato, E., Leodori, G., Puglisi‐Allegra, S., Vivacqua, G., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae210 · Cited by 32
Wang, L., Yan, Y., Zhang, L., Liu, Y., Luo, R., & Chang, Y. (2021) · Journal of Neural Transmission · doi:10.1007/s00702-020-02295-8 · Cited by 30
Altered hydroxymethylome in the substantia nigra of Parkinson’s disease
Min, S., Xu, Q., Qin, L., Li, Y., Li, Z., Chen, C., Wu, H., Han, J., Zhu, X., Jin, P., et al. (2022) · Human Molecular Genetics · doi:10.1093/hmg/ddac122 · Cited by 28
Medicinal Prospects of Targeting Tyrosinase: A Feature Review
Wang, Y., Xiong, B., Xing, S., Chen, Y., Liao, Q., Mo, J., Chen, Y., Li, Q., & Sun, H. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220915123714 · Cited by 30
Glucocerebrosidase deficiency and mitochondrial impairment in experimental Parkinson disease
Noelker, C., Lü, L., Höllerhage, M., Vulinović, F., Sturn, A., Roscher, R., Höglinger, G. U., Hirsch, É. C., Oertel, W. H., Alvarez‐Fischer, D., et al. (2015) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2015.06.030 · Cited by 31
Neuromelanin in the Human Brain: A Review and Atlas of Pigmented Cells in the Substantia Nigra
Usunoff, K. G., Itzev, D. E., Ovtscharoff, W. A., & Marani, E. (2002) · Archives of Physiology and Biochemistry · doi:10.1076/apab.110.4.257.11827 · Cited by 31
Greene, J. G., Dingledine, R. J., & Greenamyre, J. T. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.014 · Cited by 30
Variability in neuronal expression of dopamine receptors and transporters in the substantia nigra
Reyes, S., Cottam, V., Kirik, D., Double, K. L., & Halliday, G. M. (2013) · Movement Disorders · doi:10.1002/mds.25493 · Cited by 34
da Frota, M. L. C., Pires, A. S., Zeidán‐Chuliá, F., Bristot, I. J., Lopes, F. M., Pasquali, M. A. D. B., Zanotto‐Filho, A., Behr, G. A., Klamt, F., Gelain, D. P., et al. (2011) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-0983-2 · Cited by 35
“Parkinson’s disease (PD) is a neurodegenerative disease with no definitive cure so far [44], which is pathologically characterized by chronic loss of dopamine-producing neurons in the substantia nigra pars compacta [1, 2].”
BackgroundHiramoto, T., Kanda, Y., Satoh, Y., et al. (2007) · Neuroreport · doi:10.1097/wnr.0b013e3280bef9d3 · Cited by 27
“In Parkinson’s disease, dopaminergic midbrain neurons degenerate, resulting in cerebral dopamine depletion [18,19].”
BackgroundVenero, J. L., Herrera, A. J., Machado, A., & Cano, J. (1992) · British Journal Of Nutrition · doi:10.1079/bjn19920098 · Cited by 27
Reserpine prevents hydroxyl radical formation by MPP+ in rat striatum
Obata, T. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01329-3 · Cited by 28
Sun, W., Sugiyama, K., Fang, X., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2009.12.048 · Cited by 26
“…neurons in the substantia nigra (SN) pars compacta, of whichmain symptoms including resting tremor, rigidity, slow movement, gait dysfunction and postural instability (Betarbet et al., 2002; Damier et al., 1999; German et al., 1989; Halliday et al., 1996; Hirsch et al., 1988; Przedborski, 2005).”
Arabidopsis AtPARK13, Which Confers Thermotolerance, Targets Misfolded Proteins
Basak, I., Pal, R., Patil, K. S., Dunne, A., Ho, H., Lee, S., Peiris, D., Maple‐Grødem, J., Odell, M., Chang, E. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.548156 · Cited by 26
“Parkinson disease (PD)(2) is the second most common progressive neurodegenerative disorder, characterized neuropathologically by the selective loss of dopaminergic neurons in the substantia nigra pars compacta and Lewy body formation (1).”
Backgroundβ-Amyloid and α-Synuclein Cooperate To Block SNARE-Dependent Vesicle Fusion
Choi, B.-K., Kim, J.-Y., Cha, M.-Y., Mook‐Jung, I., Shin, Y.-K., & Lee, N. K. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00087 · Cited by 29
RetractedPen, G. L., Sonnier, L., Hartmann, A., Bizot, J., Trovero, F., Krebs, M., & Prochiantz, A. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.007 · Cited by 28
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Recruitment of calbindin into nigral dopamine neurons protects against MPTP‐Induced parkinsonism
Inoue, K., Miyachi, S., Nishi, K., Okado, H., Nagai, Y., Minamimoto, T., Nambu, A., & Takada, M. (2018) · Movement Disorders · doi:10.1002/mds.107 · Cited by 29
Ohm, D. T., Peterson, C. S., Lobrovich, R., Cousins, K. A. Q., Gibbons, G. S., McMillan, C. T., Wolk, D. A., Deerlin, V. M. V., Elman, L. B., Spindler, M., et al. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02210-1 · Cited by 26
Counihan, T. J., & Penney, J. B. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.2.164 · Cited by 26
Differential nicotinic receptor expression in monkey basal ganglia: Effects of nigrostriatal damage
Quik, M., Polonskaya, Y., McIntosh, J. M., & Kulak, J. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00106-9 · Cited by 29
Palomo, T., Beninger, R. J., Kostrzewa, R. M., & Archer, T. (2003) · Neurotoxicity Research · doi:10.1007/bf03033369 · Cited by 28
MPTP: A Dopaminergic Neurotoxin
Royland, J. E., & Langston, J. W. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-477-1_6 · Cited by 26
Towards improved screening of toxins for Parkinson’s risk
Shan, L., Heusinkveld, H. J., Paul, K. C., Hughes, S., Darweesh, S. K. L., Bloem, B. R., & Homberg, J. R. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00615-9 · Cited by 33
“A conceivable explanation is that the process to deplete 60 – 80% of dopaminergic neurons in the nigrostriatal pathway of PD patients — which is the threshold beyond which clinically discernible symptoms start to emerge — likely takes decades 1 together with aging.”
BackgroundKostuk, E. W., Cai, J., & Iacovitti, L. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1181-x · Cited by 29
“Subsequently, embryonic neuron preparations were carried out to obtain TH-GFP+ neurons.”
BackgroundInfluentialChoi, D., Yang, H., Gaire, S., Lee, K. A., An, J., Kim, B. G., Jou, I., Park, S. M., & Joe, E.-H. (2020) · Glia · doi:10.1002/glia.23828 · Cited by 26
Fauser, M., Ricken, M. A., Markert, F., Weis, N., Schmitt, O., Gimsa, J., Winter, C., Badstübner-Meeske, K., & Storch, A. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105404 · Cited by 27
Neuromelanin enhances the toxicity of α-synuclein in SK-N-SH cells
Li, J., Yang, J., Zhao, P., Li, S., Zhang, R., Zhang, X., Liu, D., & Zhang, B. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0753-z · Cited by 26
“Parkinson’s disease (PD) is characterized by the loss of substantia nigra (SN) neuromelanin (NM)-containing dopaminergic neurons and accumulation of inclusion bodies—Lewy bodies (LBs), which are created by the deposition of a-synuclein (a-syn) (Hirsch et al. 1988).”
BackgroundInfluentialMouse models of Parkinson's disease associated with mitochondrial dysfunction
Pickrell, A. M., Pinto, M., & Moraes, C. T. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.08.002 · Cited by 28
“Neuromelanin positive SN cells are often more susceptible in the pathology of human PD (Hirsch et al., 1988).”
BackgroundNakamura, K., & Sugaya, K. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.131583 · Cited by 25
“The amount of neuromelanin contained within the dopaminergic neurons of the midbrain has been reported to be inversely related to the relative vulnerability of these cells to IPD (Hirsch et al., 1988).”
Thibaut, F., Hirsch, É. C., Raisman‐Vozari, R., Javoy-Agid, F., & Agid, Y. (1990) · Neuroscience · doi:10.1016/0306-4522(90)90409-w · Cited by 26
Self-citationImaging behavioural complications of Parkinson’s disease
Valli, M., Mihaescu, A. S., & Strafella, A. P. (2017) · Brain Imaging and Behavior · doi:10.1007/s11682-017-9764-1 · Cited by 31
Yadav, R., Ramaswamy, P., Pal, P. K., & Christopher, R. (2019) · Annals of Indian Academy of Neurology · doi:10.4103/aian.aian_440_19 · Cited by 28
“Additionally, we can see the selective loss of dopaminergic neurons and abnormal protein inclusions in the brain.[1] At present, even though several medications are available to manage symptoms of PD.”
BackgroundTRPM1: New Trends for an Old TRP
Oancea, E., & Wicks, N. L. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-0265-3_7 · Cited by 26
“The correlation between neuromelanin content and the vulnerability of dopaminergic neurons to cell death in Parkinson’s disease [ 46 ] emphasizes the need for further investigations of the localization and function of TRPM1 in brain.”
BackgroundHeterogeneous dopamine populations project to specific subregions of the primate amygdala
Cho, Y., & Fudge, J. L. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2009.11.004 · Cited by 28
“Subpopulations of the midbrain DA neurons To define the boundaries of the classic A8-A9-A10 DAergic groups, we used landmarks previously described by Hirsch et al., and used in human and monkey studies (Hirsch et al., 1988; Francois et al., 1999) (Fig.”
MethodToxic effects of human and rodent variants of alpha‐synuclein in vivo
Landeck, N., Buck, K., & Kirik, D. (2016) · European Journal of Neuroscience · doi:10.1111/ejn.13493 · Cited by 28
“In particular, loss of dopaminergic cells in the substantia nigra is well known (Fahn et al., 1971; Hirsch et al., 1988).”
BackgroundFunctional effects of neuromelanin and synthetic melanin in model systems
Double, K. L. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0450-5 · Cited by 26
“The pigmentation of the dopaminergic neurons of the human substantia nigra pars compacta appears to underlie the especial vulnerability of these cells in Parkinson’s disease (Hirsch et al., 1988).”
Effects of melanin and manganese on dna damage and repair in PC12-derived neurons
Sava, V., Mosquera, D. I., Song, S., Cardozo‐Pelaez, F., & Sanchez‐Ramos, J. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.01.019 · Cited by 24
Selective loss of nigral neurons in Pick's disease: a morphometric study
Uchihara, T., Tsuchiya, K., & Kosaka, K. (1990) · Acta Neuropathologica · doi:10.1007/bf00334504 · Cited by 24
“In Parkinson's disease, a 50% - 77% decrease in the number of nigral neurons was reported [2, 7, 8, 12 , 26].”
BackgroundCholinergic and peptidergic systems in PSP
Javoy-Agid, F. (1994) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6641-3_16 · Cited by 23
Luo, L., Chen, J., Su, D., Chen, M., Luo, B., Pi, R., Wang, L., Shen, W., & Wang, R. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2117-4 · Cited by 23
A Parkinson’s disease gene, DJ-1, regulates astrogliosis through STAT3
Choi, D., Kwon, J.-K., & Joe, E.-H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.08.025 · Cited by 22
Fang, X., Sugiyama, K., Akamine, S., & Namba, H. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.010 · Cited by 24
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the nigrostriatal and mesolimbic systems (Hirsch et al., 1998) which leads to impairments of motor function such as rigidity, tremor, and hypokinesia (Carlsson, 1993; Hornykiewicz, 1993).”
BackgroundStriatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia
Hallett, P. J., & Brotchie, J. M. (2006) · Movement Disorders · doi:10.1002/mds.21163 · Cited by 30
Hall, H., Jewett, M. A. S., Landeck, N., Nilsson, N., Schagerlöf, U., Leanza, G., & Kirik, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064844 · Cited by 26
“Clinically, Parkinson’s disease (PD) is characterized by the presence of motor symptoms, resulting from the loss of striatal dopamine (DA) following neurodegeneration of dopaminergic cells in the substantia nigra (SN) [1,2,3].”
InfluentialLlorente‐Folch, I., Sahún, I., Contreras, L., Casarejos, M. J., Grau, J. M., Saheki, T., Mena, M. A., Satrústegui, J., Dierssen, M., & Pardo, B. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12096 · Cited by 30
“2002), the presence of neuromelanin pigment in subpopulations of DA-containing mesencephalic neurons (Hirsch et al. 1988) and the low content of mitochondria in DA neurons of the substantia nigra pars compacta (Liang et al.”
BackgroundSteffen, V. M., Santiago, M., de la Cruz, C., Revilla, E., Machado, A. M., & Cano, J. (1995) · Human & Experimental Toxicology · doi:10.1177/096032719501401102 · Cited by 23
Alterations in the nigrostriatal dopamine system after acute systemic PhIP exposure
Ağım, Z. S., & Cannon, J. R. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.01.017 · Cited by 23
“For example: 1) Dopaminergic neurons have an increased burden of oxidative stress due to constant generation of ROS during dopamine metabolism.”
BackgroundInfluentialDistribution of iron in a single neuron of patients with Parkinson's disease
Ektessabi, A. M., Yoshida, S., & Takada, K. (1999) · X-Ray Spectrometry · doi:10.1002/(sici)1097-4539(199911/12)28:6 · Cited by 23
Schuligoi, R., Fernandez, J., HEAVENS, R. P., et al. (1993) · Molecular Brain Research · doi:10.1016/0169-328x(93)90135-c · Cited by 23
Dumas, S., Javoy-Agid, F., Hirsch, É. C., Agid, Y., & Mallet, J. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490250415 · Cited by 25
Self-citationDisentangling associations between complex traits and cell types with seismic
Lai, Q., Dannenfelser, R., Roussarie, J.-P., & Yao, V. (2025) · Nature Communications · doi:10.1038/s41467-025-63753-z · Cited by 31
“PD pathophysiology is well-established, with dopaminergic neurons residing in the substantia nigra pars compacta (SNc) and ventral tegmental area (VTA) characterized as being particularly vulnerable to degeneration 29 .”
Parkinson's Disease: From Genetics to Treatments
Fan, H., Chen, S., Harn, H., & Lin, S. (2013) · Cell Transplantation · doi:10.3727/096368912x655082 · Cited by 26
O’Keeffe, G. W., Hegarty, S. V., & Sullivan, A. M. (2017) · Neuronal Signaling · doi:10.1042/ns20170027 · Cited by 21
Disturbance of sensorimotor filtering in the 6-OHDA rodent model of Parkinson's disease
Issy, A. C., Padovan‐Neto, F. E., Lazzarini, M., Bortolanza, M., & Bel, E. A. D. (2015) · Life Sciences · doi:10.1016/j.lfs.2015.01.022 · Cited by 24
“Parkinson's disease (PD) is a progressive movement disorder characterized by resting tremor, bradykinesia and rigidity, resulting mainly from progressive loss of dopaminergic neurons in the substantia nigra compacta [24] and reduction of dopamine levels in the striatum [44].”
BackgroundSim1 Is a Novel Regulator in the Differentiation of Mouse Dorsal Raphe Serotonergic Neurons
Osterberg, N., Wiehle, M., Oehlke, O., Heidrich, S., Xu, C., Fan, C., KRIEGLSTEIN, K. G., & Roussa, E. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019239 · Cited by 22
“ation of mDA is associated with Parkinson’s disease [2], defects in”
BackgroundLabel‐Free Nanoimaging of Neuromelanin in the Brain by Soft X‐ray Spectromicroscopy
Brooks, J., Everett, J. L., Lermyte, F., Tjhin, V. T., Banerjee, S., O’Connor, P. B., Morris, C. M., Sadler, P. J., Telling, N. D., & Collingwood, J. F. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202000239 · Cited by 21
Tristão, F. S. M., Amar, M., Latrous, I., Bel, E. A. D., Prediger, R. D., & Raisman‐Vozari, R. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9401-8 · Cited by 26
Environment, Genetics and Idiopathic Parkinson's Disease
Poirier, J., Kogan, S., & Gauthier, S. G. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100031334 · Cited by 27
“"(25) Recently, a direct relationship between the distribution of neuromelanin-bearing neurons in the SN and the pattern of cell loss in IPD has been elucidated.(26) These results suggest that the neuromelanin which plays a role during normal aging may also be involved in IPD and that the trigger factor(s) responsible…”
ResultMondal, R., Ahmed, S. F., & Mukherjee, N. (2024) · Inorganic Chemistry Communications · doi:10.1016/j.inoche.2024.113575 · Cited by 21
Healy-Stoffel, M., Ahmad, S. O., Stanford, J. A., & Levant, B. (2014) · Brain Research · doi:10.1016/j.brainres.2014.05.045 · Cited by 24
“…the VTA, which projects chiefly to limbic and cortical brain regions (Oades and Halliday, 1987; van Domburg and ten Donkelaar, 1991), is similar to that in the RRF, but less than in the SNpc (German et al., 1988, 1996; Hirsch et al., 1988; Hirsch, 1994; Rodríguez et al., 2001; Uhl et al., 1985).”
Immunomodulators as Therapeutic Agents in Mitigating the Progression of Parkinson’s Disease
Grimmig, B., Morganti, J., Nash, K., & Bickford, P. (2016) · Brain Sciences · doi:10.3390/brainsci6040041 · Cited by 17
“Although it is not completely understood what sets these cells apart from those of other DA pathways, the neurons of this nucleus are more susceptible to the homeostatic disturbances and degenerate significantly more compared to similar or adjacent regions [13].”
BackgroundImaging Parkinsonian Pathology in Substantia Nigra with MRI
Huddleston, D. E., Langley, J. A., Dušek, P., He, N., Faraco, C. C., Crosson, B., Factor, S. A., & Hu, X. P. (2018) · Current Radiology Reports · doi:10.1007/s40134-018-0272-x · Cited by 22
“region containing the largest nigrosome (nigrosome 1), are the earliest and most profoundly affected in PD, as compared to dopaminergic neurons in other SNc subregions and to non-pigmented neurons [23, 24].”
BackgroundWulf, M., Barkovits, K., Schork, K., Eisenacher, M., Riederer, P. F., Gerlach, M., Eggers, B., & Marcus, K. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02530-4 · Cited by 23
“A second enzyme believed to potentially play a role in NM synthesis is tyrosine hydroxylase (TH), the rate-limiting enzyme in the catecholamine–synthesis pathway, as NM is mainly restricted to brain regions containing catecholaminergic neurons (Saper and Petito 1982; Gaspar et al. 1983; Halliday et al. 1988; Hirsch et…”
Background
Metadata
- Authors
- Hirsch, E., Graybiel, A. M., & Agid, Y. A.
- Affiliations
- Massachusetts Institute of Technology (US)
- Inserm (FR)
- ORCID
- Graybiel, Ann M.
- Venue
- Nature
- Published
- 1988-07
- Volume
- 334
- Issue
- 6180
- Pages
- 345-348
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2054421268
- Semantic Scholar
- a3233ab8e74d927c8cdec03d6fc967cde7332aaf
- Cited by
- 1,301
- References
- 20
- Citations by year
- 2026: 21 · 2025: 33 · 2024: 29 · 2023: 35 · 2022: 47 · 2021: 51 · 2020: 48 · 2019: 45 · 2018: 37 · 2017: 34 · 2016: 48 · 2015: 49 · 2014: 47 · 2013: 43 · 2012: 50
- FWCI
- 23.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkinson's disease, neuromelanin, dopaminergic neurons, substantia nigra, neuronal vulnerability, MPTP, MPP+, selective neuronal degeneration, midbrain, cell loss
- MeSH terms
- Acetylcholinesterase, Dopamine, Humans, Melanins, Nerve Degeneration, Neurons, Parkinson Disease, Pyridines, Pyridinium Compounds, Tyrosine 3-Monooxygenase, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, 1-Methyl-4-phenylpyridinium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.